Announcements
- Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
- Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
- Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
- Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
- Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
- Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
- Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
- Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
More ▼
Key statistics
As of last trade Eledon Pharmaceuticals Inc (2TK:FRA) traded at 1.86, -29.55% below its 52-week high of 2.64, set on May 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.86 |
---|---|
High | 1.86 |
Low | 1.86 |
Bid | 1.86 |
Offer | 1.94 |
Previous close | 1.84 |
Average volume | 1.43k |
---|---|
Shares outstanding | 24.81m |
Free float | 23.47m |
P/E (TTM) | -- |
Market cap | 50.12m USD |
EPS (TTM) | -1.82 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 07:15 BST.
More ▼